# PAVBLU® (aflibercept) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/aflibercept

> The FDA approved PAVBLU® (aflibercept), sponsored by REGENERON PHARMACEUTICALS, INC. (REGN), on August 26, 2024.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, month only, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is PAVBLU® (aflibercept) FDA approved?

Yes. The FDA approved PAVBLU® (aflibercept), sponsored by REGENERON PHARMACEUTICALS, INC. (REGN), on August 26, 2024. SEC Form 10-Q: "On August 26, 2024, the Company filed a patent infringement lawsuit against Sandoz Inc. ("Sandoz") in the United States District Court for the District of New Jersey alleging that Sandoz's filing for FDA approval of an aflibercept 2 mg biosimilar infringed certain Company patents." [Calendar and source filings](https://sec-api.dev/pdufa/aflibercept)

Source: SEC Form 10-Q, accession 0000872589-25-000028, https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/regn-20250930.htm (retrieved 2026-11-12). Last confirmed 2025-10-28. Cite: https://sec-api.dev/pdufa/aflibercept#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | PAVBLU® (aflibercept) |
| Codes | BAY86-5321 |
| Sponsor | REGENERON PHARMACEUTICALS, INC. (REGN) https://sec-api.dev/companies/regn/catalysts |
| Indications | with neovascular, [eye disorders](https://sec-api.dev/indications/eye-disorders), wet amd and dme, [neovascular](https://sec-api.dev/indications/neovascular), [Neovascular Age-Related Macular Degeneration](https://sec-api.dev/indications/neovascular-age-related-macular-degeneration) |
| Modality | fusion_protein |
| FDA designations | priority review |

## Timeline

### February 8, 2023: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA125387 SUPPL-75 (Efficacy): submission_status AP, submission_status_date 20230208, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product EYLEA (AFLIBERCEPT)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA125387%22

### June 27, 2023: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22761355_2024_Orig1s000OtherActionLtrs.pdf%22

### August 18, 2023: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761355 ORIG-1 (Type 5 - New Formulation or New Manufacturer): submission_status AP, submission_status_date 20230818, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product EYLEA HD (AFLIBERCEPT)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761355%22

### Jan 2024: topline data readout

- Status: completed, positive. Date confidence: month. Indication: neovascular.
- First seen 2025-12-19, last confirmed 2025-12-19.
- Press release filed with the SEC (EX-99) (accession 0001171843-25-008028): "In January 2024, Alvotech announced positive top-line results from a confirmatory clinical study comparing the efficacy, safety, and immunogenicity of AVT06 to Eylea® (aflibercept) in patients with neovascular (wet) AMD." https://www.sec.gov/Archives/edgar/data/1898416/000117184325008028/exh_991.htm

### August 26, 2024: FDA approval

- Status: completed, approved. Date confidence: exact.
- First seen 2025-02-05, last confirmed 2025-10-28.
- SEC Form 10-Q (accession 0000872589-25-000028): "On August 26, 2024, the Company filed a patent infringement lawsuit against Sandoz Inc. ("Sandoz") in the United States District Court for the District of New Jersey alleging that Sandoz's filing for FDA approval of an aflibercept 2 mg biosimilar infringed certain Company patents." https://www.sec.gov/Archives/edgar/data/872589/000087258925000028/regn-20250930.htm
- SEC Form 10-Q (accession 0000872589-25-000019): "On August 26, 2024, the Company filed a patent infringement lawsuit against Sandoz Inc. ("Sandoz") in the United States District Court for the District of New Jersey alleging that Sandoz's filing for FDA approval of an aflibercept 2 mg biosimilar infringed certain Company patents." https://www.sec.gov/Archives/edgar/data/872589/000087258925000019/regn-20250630.htm
- SEC Form 10-Q (accession 0001804220-25-000022): "On August 26, 2024, the Company filed a patent infringement lawsuit against Sandoz Inc. ("Sandoz") in the United States District Court for the District of New Jersey alleging that Sandoz's filing for FDA approval of an aflibercept 2 mg biosimilar infringes certain Company patents." https://www.sec.gov/Archives/edgar/data/872589/000180422025000022/regn-20250331.htm
- SEC Form 10-K (accession 0001804220-25-000011): "On August 26, 2024, the Company filed a patent infringement lawsuit against Sandoz Inc. in the United States District Court for the District of New Jersey alleging that Sandoz's filing for FDA approval of an aflibercept 2 mg biosimilar infringes certain Company patents." https://www.sec.gov/Archives/edgar/data/872589/000180422025000011/regn-20241231.htm

### Jan 2025: interim data readout

- Status: scheduled. Date confidence: month.
- First seen 2024-11-13, last confirmed 2024-11-13.
- Press release filed with the SEC (EX-99) (accession 0000950170-24-126346): "Company product portfolio strategy and cash utilization updates, together with SPECTRA clinical trial program and interim data updates in diabetic macular edema (DME), expected in early January 2025" https://www.sec.gov/Archives/edgar/data/1650648/000095017024126346/fdmt-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-24-126346): "SPECTRA clinical trial program and interim data updates expected in early January 2025" https://www.sec.gov/Archives/edgar/data/1650648/000095017024126346/fdmt-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-24-126346): "Interim data and program update expected in 2025" https://www.sec.gov/Archives/edgar/data/1650648/000095017024126346/fdmt-ex99_1.htm

### January 10, 2025: topline data readout

- Status: completed, positive. Date confidence: exact.
- First seen 2025-01-10, last confirmed 2025-01-10.
- SEC Form 8-K (accession 0000950170-25-003832): "On January 10, 2025, the Company reported positive topline interim data from Part 1 of the SPECTRA clinical trial evaluating 4D-150 in DME and alignment with the U.S. Food and Drug Administration ("FDA") on registrational pathway for 4D-150 in DME." https://www.sec.gov/Archives/edgar/data/1650648/000095017025003832/fdmt-20250110.htm

### Feb 2025: interim data readout

- Status: scheduled. Date confidence: month. Stage: 2.
- First seen 2024-11-13, last confirmed 2024-11-13.
- Press release filed with the SEC (EX-99) (accession 0000950170-24-126346): "52-week interim data from Phase 2b cohort of PRISM clinical trial expected in February 2025 o" https://www.sec.gov/Archives/edgar/data/1650648/000095017024126346/fdmt-ex99_1.htm

### February 18, 2025: NDA/BLA acceptance

- Status: completed. Date confidence: exact. Indication: eye disorders.
- First seen 2025-02-18, last confirmed 2026-06-16.
- Press release filed with the SEC (EX-99) (accession 0001171843-25-003438): "On 18 February 2025 , the Company announced that the FDA has accepted for review a BLA for AVT 06 , Alvotech's proposed biosimilar to Eylea (aflibercept), a biologic used to treat eye disorders, including diseases which can lead to vision loss or blindness ." https://www.sec.gov/Archives/edgar/data/1898416/000117184325003438/exh_992.htm
- Press release filed with the SEC (EX-99) (accession 0001171843-25-000882): "REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT06, Alvotech's proposed biosimilar to Eylea® (aflibercept), a biologic used to treat eye disorders, including diseases which can lead to vision loss or blindness." https://www.sec.gov/Archives/edgar/data/1898416/000117184325000882/exh_991.htm
- SEC prospectus (424B) (accession 0000930413-26-001864): "In February 2025, the FDA accepted our BLA for AVT06 as a proposed biosimilar to Eylea (aflibercept) for the treatment of patients with neovascular (wet) age related macular degeneration (AMD), macular edema, and diabetic retinopathy." https://www.sec.gov/Archives/edgar/data/1898416/000093041326001864/c116682_424b5.htm
- SEC prospectus (424B) (accession 0000930413-26-001857): "In February 2025, the FDA accepted our BLA for AVT06 as a proposed biosimilar to Eylea (aflibercept) for the treatment of patients with neovascular (wet) age related macular degeneration (AMD), macular edema, and diabetic retinopathy." https://www.sec.gov/Archives/edgar/data/1898416/000093041326001857/c116682_424b5.htm

### Q3 2025: trial start

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2025-02-28, last confirmed 2025-05-08.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-067013): "Initiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) expected in Q3 2025, with topline data from both 4FRONT-1 and 4FRONT-2 expected in H2 2027" https://www.sec.gov/Archives/edgar/data/1650648/000095017025067013/fdmt-ex99_1.htm
- SEC Form 10-K (accession 0000950170-25-030056): "For example, in 2025, we plan to initiate Phase 3 studies comparing a single dose of 4D-150 3E10 vg/eye to on-label aflibercept 2mg Q8 weeks." https://www.sec.gov/Archives/edgar/data/1650648/000095017025030056/fdmt-20241231.htm

### August 22, 2025: interim data readout

- Status: completed, positive. Date confidence: exact.
- First seen 2024-11-13, last confirmed 2026-03-18.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-113949): "Announced positive long-term interim results (data cutoff: August 22, 2025)" https://www.sec.gov/Archives/edgar/data/1650648/000119312526113949/fdmt-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-273340): "Announced positive long-term interim results (data cutoff: August 22, 2025)" https://www.sec.gov/Archives/edgar/data/1650648/000119312525273340/fdmt-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-067013): "52-week interim data update expected at a scientific conference in Q3 2025 o" https://www.sec.gov/Archives/edgar/data/1650648/000095017025067013/fdmt-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-030020): "52-week interim data update from Part 1 of SPECTRA expected at a scientific conference in Q3 2025" https://www.sec.gov/Archives/edgar/data/1650648/000095017025030020/fdmt-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-067013): "Interim data from AEROW clinical trial and program update expected at a scientific conference in H2 2025" https://www.sec.gov/Archives/edgar/data/1650648/000095017025067013/fdmt-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-030020): "Interim data and program update from AEROW clinical trial expected at a scientific conference in H2 2025" https://www.sec.gov/Archives/edgar/data/1650648/000095017025030020/fdmt-ex99_1.htm
- SEC Form 8-K (accession 0000950170-25-003832): "The Company will present the results from Part 1 of the SPECTRA clinical trial in a corporate webcast on February 10, 2025, and will present a 52-week interim data update at a scientific conference in mid-2025." https://www.sec.gov/Archives/edgar/data/1650648/000095017025003832/fdmt-20250110.htm
- SEC Form 8-K (accession 0000950170-25-003832): "52-week interim data update expected at a scientific conference in mid-2025" https://www.sec.gov/Archives/edgar/data/1650648/000095017025003832/fdmt-20250110.htm
- SEC Form 8-K (accession 0000950170-25-003832): "Interim data update expected to be presented in mid-2025 at a scientific conference, including available measurements of ppFEV1, CFQ-R-R (quality-of-life instrument), lung clearance index and serial airway biopsies and brushings collected at 4-8 weeks and beyond 12 months post-dosing" https://www.sec.gov/Archives/edgar/data/1650648/000095017025003832/fdmt-20250110.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-24-126346): "Interim data and program update from AEROW clinical trial is expected in mid-2025" https://www.sec.gov/Archives/edgar/data/1650648/000095017024126346/fdmt-ex99_1.htm

### August 26, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Neovascular Age-Related Macular Degeneration; Diabetic Macular Edema.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06491914 (A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-08-26 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals; Results First Posted 2026-09-18." https://clinicaltrials.gov/study/NCT06491914

### Q4 2025: topline data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2024-11-14, last confirmed 2024-11-14.
- SEC Form 10-Q (accession 0001558370-24-015613): "We expect the SOL-1 trial to be fully enrolled with all subjects randomized by the end of 2024 and to present topline data from the SOL-1 trial during the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1393434/000155837024015613/ocul-20240930x10q.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-24-118284): "Topline data from the SOL-1 trial are now expected during the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1393434/000110465924118284/tm2428320d2_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-24-118284): "2024 with topline data expected in Q4 2025" https://www.sec.gov/Archives/edgar/data/1393434/000110465924118284/tm2428320d2_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-24-118284): "We are making outstanding progress on enrollment in the two complementary studies in our registrational program for AXPAXLI in wet AMD, SOL-1 and SOL-R. I'm thrilled to share that SOL-1 has reached a key enrollment milestone, as we have now 'flipped the switch' to allow direct enrollment of subjects into SOL-R. We expect to complete SOL-1 randomization by year-end, with topline data to follow in the fourth quarter of 2025." https://www.sec.gov/Archives/edgar/data/1393434/000110465924118284/tm2428320d2_ex99-1.htm

### November 19, 2025: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761355 SUPPL-10 (Efficacy): submission_status AP, submission_status_date 20251119, review_priority PRIORITY; sponsor_name REGENERON PHARMACEUTICALS; product EYLEA HD (AFLIBERCEPT)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761355%22

### December 1, 2025: interim data readout

- Status: completed, positive. Date confidence: exact.
- First seen 2025-08-11, last confirmed 2026-03-18.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-113949): "Announced positive long-term interim results from the AEROW Phase 1/2 clinical trial (data cut-off: December 1, 2025)" https://www.sec.gov/Archives/edgar/data/1650648/000119312526113949/fdmt-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-106243): "Interim data from AEROW clinical trial and program update expected in Q4 2025" https://www.sec.gov/Archives/edgar/data/1650648/000095017025106243/fdmt-ex99_1.htm

### Q1 2026: topline data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2025-03-03, last confirmed 2025-11-04.
- Press release filed with the SEC (EX-99) (accession 0001104659-25-105914): "Exceptional execution and retention in AXPAXLI wet AMD registrational program continue with topline data on track for SOL-1 in 1Q 2026 and SOL-R in 1H 2027" https://www.sec.gov/Archives/edgar/data/1393434/000110465925105914/tm2530039d1_ex99-1.htm
- SEC Form 8-K (accession 0001104659-25-094724): "The Company continues to expect topline results for the SOL-1 trial to be available in the first quarter of 2026 after the completion of the Week 52 visits for all subjects in the trial." https://www.sec.gov/Archives/edgar/data/1393434/000110465925094724/tm2527344d2_8k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-073909): "SOL-1 remains on track for 1Q 2026 topline data" https://www.sec.gov/Archives/edgar/data/1393434/000110465925073909/tm2522503d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-073909): ""With SOL-1 on track for topline data in the first quarter of 2026, followed by SOL-R topline data in the first half of 2027, we are building what we expect to be a powerful and highly differentiated clinical profile for AXPAXLI." https://www.sec.gov/Archives/edgar/data/1393434/000110465925073909/tm2522503d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-044349): "SOL-1 retention remains exceptional as trial is on track for 1Q 2026 topline data readout" https://www.sec.gov/Archives/edgar/data/1393434/000110465925044349/tm2513949d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-044349): "Topline data are on track for 1Q 2026." https://www.sec.gov/Archives/edgar/data/1393434/000110465925044349/tm2513949d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-019462): "52 to enable re-dosing at 12 months, with topline data expected in 1Q 2026." https://www.sec.gov/Archives/edgar/data/1393434/000110465925019462/tm258051d1_ex99-1.htm

### Feb 2026: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 3.
- First seen 2025-08-05, last confirmed 2026-11-09.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-010633): "SOL-1 (Phase 3, wet AMD) superiority trial on track for topline data in the second half of February 2026." https://www.sec.gov/Archives/edgar/data/1393434/000110465926010633/tm265061d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-105914): "SOL-1 (Phase 3, wet AMD) superiority trial on track for Q1 2026 topline data with exceptional retention and protocol adherence." https://www.sec.gov/Archives/edgar/data/1393434/000110465925105914/tm2530039d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-073909): "SOL-1 (Phase 3, wet AMD) retention and protocol adherence continues to be exceptional as topline data remains on track for 1Q 2026." https://www.sec.gov/Archives/edgar/data/1393434/000110465925073909/tm2522503d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-089443): "In February 2026, Ocular reported positive SOL-1 Week 52 topline data." https://www.sec.gov/Archives/edgar/data/1393434/000110465926089443/tm2621618d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-055241): "In February 2026, Ocular reported positive SOL-1 Week 52 topline data." https://www.sec.gov/Archives/edgar/data/1393434/000110465926055241/tm2613442d1_ex99-1.htm
- SEC Form 10-Q (accession 0001104659-26-124155): "In February 2026, we announced positive topline Week 52 results for the SOL-1 trial." https://www.sec.gov/Archives/edgar/data/1393434/000110465926124155/ocul-20260930x10q.htm
- SEC Form 10-Q (accession 0001104659-26-089450): "In February 2026, we announced positive topline Week 52 results for the SOL-1 trial." https://www.sec.gov/Archives/edgar/data/1393434/000110465926089450/ocul-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-055256): "In February 2026, we announced positive topline Week 52 results for the SOL-1 trial, a repeat-dosing registrational Phase 3 clinical trial, to assess the safety and efficacy of AXPAXLI in subjects with wet AMD." https://www.sec.gov/Archives/edgar/data/1393434/000110465926055256/ocul-20260331x10q.htm

### April 2, 2026: label expansion decision

- Status: completed, approved. Date confidence: exact.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- openFDA Drugs@FDA: "BLA761355 SUPPL-5 (Efficacy): submission_status AP, submission_status_date 20260402, review_priority STANDARD; sponsor_name REGENERON PHARMACEUTICALS; product EYLEA HD (AFLIBERCEPT)." https://api.fda.gov/drug/drugsfda.json?search=application_number:%22BLA761355%22

### Q3 2026: NDA/BLA submission

- Status: scheduled. Date confidence: quarter.
- First seen 2026-08-03, last confirmed 2026-11-09.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-089443): "Pre-NDA meeting scheduled with FDA in Q3 2026 with the NDA submission to follow the Section 505(b)(2) pathway which could accelerate the review timeline by up to 60 days" https://www.sec.gov/Archives/edgar/data/1393434/000110465926089443/tm2621618d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-124151): "NDA submission for wet AMD on track for 4Q 2026 following upcoming SOL-R interim Week 52 safety analysis" https://www.sec.gov/Archives/edgar/data/1393434/000110465926124151/tm2629079d2_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-124151): "SOL-R Week 52 safety analysis to be conducted in 4Q 2026, with interim safety data to be included in the planned AXPAXLI NDA submission to FDA." https://www.sec.gov/Archives/edgar/data/1393434/000110465926124151/tm2629079d2_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-089443): "AXPAXLITM wet AMD NDA submission on track for Q4 2026 following positive Type C Meeting with the U.S. FDA in May 2026" https://www.sec.gov/Archives/edgar/data/1393434/000110465926089443/tm2621618d1_ex99-1.htm

### Sep 2026: trial start

- Status: completed. Date confidence: month. Stage: 3.
- First seen 2026-11-12, last confirmed 2026-11-12.
- SEC Form 10-Q (accession 0001193125-26-458477): "In September 2026, we initiated 4SIGHT, our Phase 3 clinical trial evaluating 4D-150 in treatment-naïve patients with DME." https://www.sec.gov/Archives/edgar/data/1650648/000119312526458477/fdmt-20260930.htm

### September 18, 2026: topline data readout

- Status: completed. Date confidence: exact. Stage: 3. Indication: Neovascular Age-Related Macular Degeneration; Diabetic Macular Edema.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06491914 (A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2025-08-26 (ACTUAL); Lead Sponsor Regeneron Pharmaceuticals; Results First Posted 2026-09-18." https://clinicaltrials.gov/study/NCT06491914?tab=results

### Q4 2026: NDA/BLA submission

- Status: scheduled. Date confidence: quarter.
- First seen 2026-09-28, last confirmed 2026-09-28.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-403481): "The company is planning to submit a three-indication BLA for Zenkuda in 4Q2026." https://www.sec.gov/Archives/edgar/data/1468748/000119312526403481/d185059dex991.htm

### Q1 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2025-08-05, last confirmed 2026-05-05.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-055241): "SOL-R Phase 3 non-inferiority trial in wet AMD on track for topline readout in 1Q 2027" https://www.sec.gov/Archives/edgar/data/1393434/000110465926055241/tm2613442d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-055241): "SOL-R (Phase 3, wet AMD) non-inferiority trial remains on track for topline data in 1Q 2027." https://www.sec.gov/Archives/edgar/data/1393434/000110465926055241/tm2613442d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-010633): "Completed randomization of 631 subjects in SOL-R Phase 3 non-inferiority trial in December 2025; timing of topline results accelerated and now anticipated in 1Q 2027" https://www.sec.gov/Archives/edgar/data/1393434/000110465926010633/tm265061d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-010633): "SOL-R (Phase 3, wet AMD) non-inferiority trial completed randomization in December 2025, accelerating expected topline data to 1Q 2027." https://www.sec.gov/Archives/edgar/data/1393434/000110465926010633/tm265061d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-105914): "SOL-R (Phase 3, wet AMD) non-inferiority trial achieves target randomization of 555 subjects and remains on track for 1H 2027 topline data." https://www.sec.gov/Archives/edgar/data/1393434/000110465925105914/tm2530039d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-073909): "SOL-R (Phase 3, wet AMD) rescue criteria streamlined and simplified with topline data expected in 1H 2027." https://www.sec.gov/Archives/edgar/data/1393434/000110465925073909/tm2522503d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-26-055241): "Along those lines, SOL-R is progressing expeditiously, with topline data on track for the first quarter of 2027, while HELIOS-3 also remains ongoing." https://www.sec.gov/Archives/edgar/data/1393434/000110465926055241/tm2613442d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-105914): "Ocular will continue to allow randomization of subjects currently in the loading phase of the trial to maintain its commitment to both patients and investigators, with topline data remaining on track for the first half of 2027." https://www.sec.gov/Archives/edgar/data/1393434/000110465925105914/tm2530039d1_ex99-1.htm
- SEC Form 8-K (accession 0001104659-25-094724): "The Company continues to expect topline results for the SOL-R trial to be available in the first half of 2027." https://www.sec.gov/Archives/edgar/data/1393434/000110465925094724/tm2527344d2_8k.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-073909): "SOL-R rescue criteria streamlined and simplified with topline data expected in 1H 2027" https://www.sec.gov/Archives/edgar/data/1393434/000110465925073909/tm2522503d1_ex99-1.htm
- Press release filed with the SEC (EX-99) (accession 0001104659-25-073909): "SOL-R has completed enrollment and, based on its projected randomization timeline, Ocular expects to report topline data in 1H 2027." https://www.sec.gov/Archives/edgar/data/1393434/000110465925073909/tm2522503d1_ex99-1.htm

### Q2 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3.
- First seen 2025-08-11, last confirmed 2026-11-12.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-458394): "Enrollment completed in February 2026 and randomization completed (N=523) in March 2026; topline data expected in Q2 2027" https://www.sec.gov/Archives/edgar/data/1650648/000119312526458394/fdmt-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-349160): "Enrollment completed in February 2026 and randomization completed (N=523) in March 2026; topline data expected in Q2 2027" https://www.sec.gov/Archives/edgar/data/1650648/000119312526349160/fdmt-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-211904): "Enrollment completed in February 2026 and randomization completed (N=523) in March 2026; topline data expected in H1 2027" https://www.sec.gov/Archives/edgar/data/1650648/000119312526211904/fdmt-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-113949): "Enrollment completed in February 2026 with over 500 patients expected to be randomized; topline data expected in H1 2027" https://www.sec.gov/Archives/edgar/data/1650648/000119312526113949/fdmt-ex99_1.htm
- SEC Form 8-K (accession 0001193125-25-314167): "The Company continues to expect to complete enrollment of 4FRONT-1 in Q1 2026 and to disclose topline data in H1 2027." https://www.sec.gov/Archives/edgar/data/1650648/000119312525314167/fdmt-20251210.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-273340): "Enrollment rate exceeds initial expectations, with over 200 patients randomized to date, and is on track to complete enrollment in Q1 2026, with 52-week topline data expected in H1 2027" https://www.sec.gov/Archives/edgar/data/1650648/000119312525273340/fdmt-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-106243): ""Rapid enrollment in 4FRONT-1 has enabled us to accelerate the topline data expectation to the first half of 2027, and we initiated 4FRONT-2 ahead of schedule." https://www.sec.gov/Archives/edgar/data/1650648/000095017025106243/fdmt-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-106243): "52-week topline data expected in H1 2027, accelerated from previous guidance of H2 2027" https://www.sec.gov/Archives/edgar/data/1650648/000095017025106243/fdmt-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-458394): "Completed enrollment and randomization of the 4FRONT-2 Global Phase 3 clinical trial, the second of two pivotal trials of 4D-150 in wet AMD; topline data for 4FRONT-1 and 4FRONT-2 expected in Q2 2027 and H2 2027, respectively" https://www.sec.gov/Archives/edgar/data/1650648/000119312526458394/fdmt-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-349160): "4D-150 4FRONT-1 Phase 3 topline data expected in Q2 2027" https://www.sec.gov/Archives/edgar/data/1650648/000119312526349160/fdmt-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-211904): "4D-150 4FRONT-1 wet AMD Phase 3 randomization complete (N=523); topline data expected in H1 2027" https://www.sec.gov/Archives/edgar/data/1650648/000119312526211904/fdmt-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-113949): "Completed enrollment in 4D-150 4FRONT-1 wet AMD Phase 3 trial within approximately 11 months, ahead of initial projections and reflecting strong interest from investigators and patients; topline data expected in H1 2027" https://www.sec.gov/Archives/edgar/data/1650648/000119312526113949/fdmt-ex99_1.htm

### 2H 2027: topline data readout

- Status: scheduled. Date confidence: half. Stage: 3. Indication: wet AMD and DME.
- First seen 2025-01-10, last confirmed 2026-11-12.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-349160): "Completed enrollment for 4D-150 4FRONT-2 wet AMD Phase 3; topline data expected in H2 2027" https://www.sec.gov/Archives/edgar/data/1650648/000119312526349160/fdmt-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-067013): "Initiation of second 4D-150 Phase 3 clinical trial (4FRONT-2) expected in Q3 2025, with topline data from both 4FRONT-1 and 4FRONT-2 expected in H2 2027" https://www.sec.gov/Archives/edgar/data/1650648/000095017025067013/fdmt-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-067013): "Our strong balance sheet provides us an expected operational runway into 2028, enabling us to deliver topline results from both wet AMD Phase 3 clinical trials in H2 2027 without raising additional capital." https://www.sec.gov/Archives/edgar/data/1650648/000095017025067013/fdmt-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-030020): "4FRONT Phase 3 program in wet AMD on track with initiation of 4FRONT-1 expected in March 2025 and 4FRONT-2 in Q3 2025, with topline data from both studies expected in 2H 2027" https://www.sec.gov/Archives/edgar/data/1650648/000095017025030020/fdmt-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-349160): ""With topline data from both 4FRONT-1 and 4FRONT-2 in wet AMD expected in 2027, our DME Phase 3 expected to initiate in the third quarter and our Investor Day planned in October, we are well positioned to advance 4D-150 as a potential paradigm-changing backbone therapy for patients with wet AMD and DME."" https://www.sec.gov/Archives/edgar/data/1650648/000119312526349160/fdmt-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-458394): "Enrollment completed in June 2026 and randomization completed (N=531) in August 2026; topline data expected in H2 2027 o" https://www.sec.gov/Archives/edgar/data/1650648/000119312526458394/fdmt-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-349160): "Enrollment completed in June 2026 with N>500 expected to be randomized; topline data expected in H2 2027 o" https://www.sec.gov/Archives/edgar/data/1650648/000119312526349160/fdmt-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-211904): "4FRONT - 2 enrollment completion expected in H2 2026; topline data expected in H2 2027" https://www.sec.gov/Archives/edgar/data/1650648/000119312526211904/fdmt-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-211904): "Enrollment completion expected in H2 2026; topline data expected in H2 2027 o" https://www.sec.gov/Archives/edgar/data/1650648/000119312526211904/fdmt-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-26-113949): "Ex-U.S. site activation and patient screening accelerating across Europe and Asia-Pacific; enrollment remains on track to be completed in H2 2026, with topline data expected in H2 2027 o" https://www.sec.gov/Archives/edgar/data/1650648/000119312526113949/fdmt-ex99_1.htm
- SEC Form 8-K (accession 0001193125-25-314167): "The Company also continues to expect to complete enrollment of 4FRONT-2 in H2 2026 and to disclose topline data in H2 2027." https://www.sec.gov/Archives/edgar/data/1650648/000119312525314167/fdmt-20251210.htm
- Press release filed with the SEC (EX-99) (accession 0001193125-25-273340): "Enrollment remains on track to be completed in H2 2026, with 52-week topline data expected in H2 2027 o" https://www.sec.gov/Archives/edgar/data/1650648/000119312525273340/fdmt-ex99_1.htm

### Q1 2028: topline data readout

- Status: scheduled. Date confidence: quarter.
- First seen 2026-08-03, last confirmed 2026-11-09.
- Press release filed with the SEC (EX-99) (accession 0001104659-26-124151): "SOL-R primary endpoint timing updated to Week 40 with topline results on track for 1Q 2028 after key secondary endpoints are evaluated." https://www.sec.gov/Archives/edgar/data/1393434/000110465926124151/tm2629079d2_ex99-1.htm
- SEC Form 10-Q (accession 0001104659-26-124155): "Topline data for the SOL-R trial are expected to be available in the first quarter of 2028." https://www.sec.gov/Archives/edgar/data/1393434/000110465926124155/ocul-20260930x10q.htm
- SEC Form 10-Q (accession 0001104659-26-124155): "We expect that direct research and development expenses for our products and product candidates will increase for the remainder of 2026 and beyond as we prepare for the planned NDA submission for AXPAXLI for wet AMD, progress the SOL-R trial toward topline data expected in the first quarter of 2028, enroll additional patients in the SOL-X and HELIOS-3 trials, and perform increased registration-enabling manufacturing scale-up activities for AXPAXLI." https://www.sec.gov/Archives/edgar/data/1393434/000110465926124155/ocul-20260930x10q.htm
- SEC Form 10-Q (accession 0001104659-26-124155): "We expect that direct research and development expenses for our products and product candidates will continue to increase for the remainder of 2026 and beyond as we prepare for the planned NDA submission for AXPAXLI for wet AMD, progress the SOL-R trial toward topline data expected in the first quarter of 2028, enroll additional patients in the SOL-X and HELIOS-3 trials, and perform increased registration-enabling manufacturing scale-up activities for AXPAXLI." https://www.sec.gov/Archives/edgar/data/1393434/000110465926124155/ocul-20260930x10q.htm
- SEC Form 10-Q (accession 0001104659-26-089450): "Topline data for the SOL-R trial are expected to be available in the first quarter of 2028." https://www.sec.gov/Archives/edgar/data/1393434/000110465926089450/ocul-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-089450): "We expect that direct research and development expenses for our products and product candidates will increase for the remainder of 2026 and beyond as we prepare for the planned NDA submission for AXPAXLI for wet AMD, progress the SOL-R trial toward topline data expected in the first quarter of 2028, enroll additional patients in the SOL-X and HELIOS-3 trials, and perform increased registration-enabling manufacturing scale-up activities for AXPAXLI." https://www.sec.gov/Archives/edgar/data/1393434/000110465926089450/ocul-20260630x10q.htm
- SEC Form 10-Q (accession 0001104659-26-089450): "We expect that direct research and development expenses for our products and product candidates will continue to increase for the remainder of 2026 and beyond as we prepare for the planned NDA submission for AXPAXLI for wet AMD, progress the SOL-R trial toward topline data expected in the first quarter of 2028, enroll additional patients in the SOL-X and HELIOS-3 trials, and perform increased registration-enabling manufacturing scale-up activities for AXPAXLI." https://www.sec.gov/Archives/edgar/data/1393434/000110465926089450/ocul-20260630x10q.htm

## Same indication

- [Biosimilar](https://sec-api.dev/pdufa/biosimilar) (ALVO)
- [Eylea® (eylea)](https://sec-api.dev/pdufa/eylea) (REGN)
- [Otx-tki (axitinib implant)](https://sec-api.dev/pdufa/otx-tki-axitinib-implant) (OCUL)
- [Lucentis® (ranibizumab)](https://sec-api.dev/pdufa/ranibizumab) (ABBV)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/aflibercept.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "PAVBLU® (aflibercept) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/aflibercept

```bibtex
@misc{secapidev_pdufa_aflibercept_20261116,
  title        = {PAVBLU® (aflibercept) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/aflibercept}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_aflibercept_20261116","title":"PAVBLU® (aflibercept) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/aflibercept","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
